GENERAL18 Sept 2026
Dr Reddy's signs India distribution deal for Takeda's Qdenga dengue vaccine
Dr Reddy's Laboratories has signed a deal with Japan's Takeda to promote and distribute the Qdenga dengue vaccine in India. India's drug regulator has already approved it for children and adults — the first dengue vaccine cleared here. It should reach India in the first half of 2027, given in two doses three months apart, and no screening is needed before use.
Key Statutory Highlights
- Dr Reddy's Laboratories signed an agreement with Japanese drugmaker Takeda to promote and distribute the Qdenga dengue vaccine in India.
- Qdenga is the first dengue vaccine approved in India and is cleared for use in both children and adults.
- Qdenga is given as two 0.5 ml doses three months apart and can be used regardless of any prior dengue infection, so no pre-vaccination screening is needed.
Actionable Advice for Taxpayers / Founders:If dengue is a concern for you or your family, speak to a doctor about whether Qdenga may suit you, and note that it is expected in India only in the first half of 2027.
Statutory Disclaimer: TaxQue Shorts are AI-assisted editorial briefs for compliance awareness. This brief has not passed every source check; confirm the original notification before acting. This does not constitute formal legal or CA counsel.
TaxQue News Desk
Share: